Stockscreener 앱 받기
39.05
0.96%
-0.38
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Zacks Investment Research
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? - Zacks Investment Research
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility - The Motley Fool
Where Will Novo Stock Be in 10 Years? - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Zacks Investment Research
$Novo-Nordisk A/S (NVO.US)$ A bullish breakout above the 25-day moving average carries a 70% probability of further upside. It is even more favorable if today's closing price is higher than yesterday's and there is no upper shadow. - Moomoo
Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk - Greater Geneva Bern area (GGBa)
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition - Yahoo Finance
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data - TipRanks
Novo's CagriSema helped women lose 25% of weight on average, analysis shows - Reuters
Prothena's Partnership Strategy: Growth Driver or Limitation? - Zacks Investment Research
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis - CNBC
Denmark’s Novo-Fueled Economy Faces Lower Growth, Watchdog Says - Bloomberg.com
Price to earnings forward of Novo Nordisk A/S Class B – LSIN:0QIU - TradingView
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo Nordisk (NVO) repurchased 39.1 million B shares; treasury shares total 1.2% of share capital. - Stock Titan
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Zacks Investment Research
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Yahoo Finance
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher - The Motley Fool
Novo Nordisk and Eli Lilly Just Got Some Fantastic News - The Motley Fool
Novo Nordisk A/S (NVO) options chain - Yahoo Finance Australia
Novo-Nordisk A/S (NVO) Stock Forum and Discussion - Moomoo
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know - TradingKey
Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today - CryptoRank
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Novo Nordisk A/S : UBS remains Neutral - marketscreener.com
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback - Yahoo Finance
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now? - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum - Zacks Investment Research
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Yahoo Finance
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Zacks Investment Research
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Yahoo Finance
Novo Nordisk A/S: Dividend historical data and projections - marketscreener.com
GLP-1 weight-loss drugs slow biological aging, recent studies show - NewsNation
1.28%
자본화:
|
볼륨(24시간):